# Malin Corporation

Malin Corporation is a Corporate Investor based in Dublin, Ireland.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Dublin, Ireland
- **Region:** Europe
- **Address:** 50 Richmond Street South, Dublin 2, D02 FK02, Ireland
- **Founded:** 2015
- **Assets under management:** Undisclosed
- **Website:** malinplc.com
- **LinkedIn:** https://www.linkedin.com/company/malin-plc

## Regulatory record

- **Reports private funds:** No

## About

Malin Corporation was formed in 2015 by serial life-sciences executive Liam Daniel, who previously chaired Elan Corporation before its $8.6B sale to Perrigo. The firm operates as an Irish public limited company (plc) listed on Euronext Dublin, a structure deliberately chosen to provide permanent, locked-up capital for an asset class where liquidity events are measured in decades, not quarters. Daniel brought a deep operating background rather than a pure fund-management pedigree, shaping Malin as a hands-on partner rather than a passive financial investor. The firm deploys capital exclusively into the life-sciences sector, with a stated focus on companies developing innovative therapeutic platforms and healthcare technologies. Malin takes concentrated positions — typically majority or significant minority stakes — allowing it to influence board-level strategy and operational direction. Historically, its portfolio has included companies advancing through clinical trials and regulatory approvals, where extended development timelines make venture-style fund structures impractical. The geographic footprint has centered on Ireland and the United Kingdom, though underlying portfolio companies often pursue FDA approval pathways that make the US a critical end market. Specific holdings and co-investors are not systematically disclosed, reflecting the plc's relatively light public reporting cadence. The firm is headquartered at The Lennox Building on Richmond Street South in Dublin, a commercial property it owns directly. Key governance transitions are underway: CEO and Company Secretary Fiona Dunlevy is slated to depart in May 2026, while founder Liam Daniel serves as Executive Chair after previously holding the Non-Executive Chair role. Major shareholders include Pentwater Capital Management, the Florida-based hedge fund manager, with approximately 28.34% of the equity, and the Ireland Strategic Investment Fund, the sovereign development fund, alongside individual shareholder Sean O'Driscoll at roughly 11.96%. Malin does not operate adjacent philanthropic foundations or co-investor clubs as separate branded entities. Malin's structural differentiator is its identity as a publicly traded, permanent-capital holding company in an industry dominated by finite-life venture funds. This architecture eliminates the forced-exit problem that plagues biotech venture — where fund-life constraints push portfolio companies toward premature IPOs or fire sales. The trade-off is the scrutiny and disclosure obligations of a listed entity, which has historically meant operating with a leaner public profile than peer biotech investment firms. The upcoming CEO departure marks a governance inflection point that will define the firm's next phase of investment stewardship.

## Sectors

- Healthcare Services
- Biotechnology

## People

- Liam Daniel — Executive Chair
- Fiona Dunlevy — CEO and Company Secretary (departing May 2026)

## Questions

### Who runs investment decisions at Malin Corporation?

Investment and strategic decisions are led by founder Liam Daniel, who serves as Executive Chair. Daniel's background includes chairing Elan Corporation, a major Irish biotech. The firm's small, Dublin-based team operates with a lean governance structure, and no separate investment committee is publicly identified.

### How is Malin Corporation different from a traditional venture capital fund?

Malin is a publicly listed plc, not a closed-end fund. This permanent-capital structure means it faces no redemption timelines or pressure to exit portfolio companies before they reach clinical or regulatory maturity. The trade-off is public-market disclosure requirements and mark-to-market volatility on its balance sheet.

### What kind of positions does Malin typically take in portfolio companies?

Malin targets concentrated, influential stakes — usually majority or significant minority positions — rather than the small, diversified equity slices common in institutional venture portfolios. This allows the firm to place directors on boards and shape operational strategy directly.

### Is Malin actively making new investments?

Malin's investment pace has historically been episodic rather than programmatic, reflecting the thin pipeline of life-sciences assets that meet its concentrated-position threshold. Public disclosures suggest the firm focuses heavily on managing and advancing existing portfolio positions through clinical and regulatory milestones.

## Related profiles

- [Malden Retirement Board](https://altss.com/profile/malden-retirement-board)
- [Mallard Financial Partners](https://altss.com/profile/mallard-financial-partners)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/malin-corporation

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology